

AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended): A method of suppressing a respiratory syncytial virus (RSV) infection in an individual who has been exposed to RSV, comprising administering a composition to the respiratory tract of said individual, said composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5'-CG-3', wherein the polynucleotide is greater than 6 and less than about 200 nucleotides in length, wherein RSV antigen, ~~is not administered in conjunction with administration of said composition, wherein an immunostimulatory cytokine, and a non-nucleic acid adjuvant are [[is]]~~ not administered in conjunction with administration of said composition and wherein said composition is administered in an amount sufficient to suppress an RSV infection.
2. (original): The method of claim 1, wherein the ISS comprises the sequence 5'-T, C, G-3'.
3. (original): The method of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3' or 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3'.
4. (original): The method of claim 3, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCC-3', 5'-AACGTTCG-3', 5'-GACGTTCC-3', and 5'-GACGTTCG-3'.
5. (original): The method of claim 1, wherein the ISS comprises the sequence 5'-TGACTGTGAAACGTTCGAGATGA-3' (SEQ ID NO:1).
6. (original): The method of claim 1, wherein the individual is a mammal.

7. (canceled)

8. (previously presented): The method of claim 1, wherein administration is to a lung.

9. (previously presented): The method of claim 1, wherein administration is to the nasal passages.

10. (original): The method of claim 1, wherein the suppression comprises a reduction of RSV titer in a biological sample from said individual.

11. (Currently amended): A kit for use in suppressing a respiratory syncytial virus (RSV) infection in an individual exposed to RSV, comprising:

 a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-CG-3', wherein the polynucleotide is greater than 6 and less than about 200 nucleotides in length and wherein said kit does not comprise RSV antigen, [[or]] an immunostimulatory cytokine, or a non-nucleic acid adjuvant; and

 instructions for administration of said composition to the respiratory tract of an individual to suppress an RSV infection.

12. (original): The kit of claim 11, wherein the ISS comprises the sequence 5'-T, C, G-3'.

13. (original): The kit of claim 11, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3' or 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3'.

14. (original): The kit of claim 13, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCC-3', 5'-AACGTTCG-3', 5'-GACGTTCC-3' and 5'-GACGTTCG-3'.

15. (original): The kit of claim 11, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO:1).